13
Oct
2017

Spark Gene Therapy Sails Thru AdComm, Broad Institute Nuzzles Up to Deerfield, Pfizer’s Cancer Deal in Africa

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
 

You may also like

GSK Doubles Down on China, Sarepta Rebounds, and Frazier’s $1.3B Fund
Sarepta Crashes, Abivax Soars, & Sanofi Buys Another Vaccine Platform
Merck Bets $10B on COPD, AbbVie Buys In Vivo CAR-T, & FDA Transparency
Avidity Advances in FSHD, Insmed Passes PAH Test, Merck Delivers with Oral PCSK9